EDISON, N.J., Dec. 8, 2015 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, reports positive results regarding CMX157's significantly enhanced potency against hepatitis B virus (HBV), now determined to be 97-fold compared to tenofovir (TFV), based on state-of-the-art in vitro studies. These results from head-to-head studies support CMX157's potential for an enhanced safety profile compared to Gilead's tenofovir DF (Viread®).
The data were presented at HEP DART 2015 by John Sullivan-Bolyai, MD, MPH, Chief Medical Officer of ContraVir, who stated, "These compelling results, derived from state-of-the-art in vitro studies, show that CMX157 potentially demonstrates equal, if not better, antiviral activity at low doses compared to Viread®. Furthermore, we've consistently shown that CMX157 not only has less cytotoxicity than Viread® in vitro along with a low potential for mitochondrial toxicity, but should significantly reduce the amount of TFV exposure outside the liver, further enhancing the safety profile of CMX157 compared to Viread®. These favorable results provide a solid foundation for advancing our Hepatitis B clinical program."
The presentation is available on the ContraVir website, www.contravir.com.
CMX157 demonstrates a potential enhanced safety profile compared to Viread® (Tenofovir DF, TDF)
CMX157 is 97-fold more active against HBV than TFV in vitro
CMX157 is highly liver targeted (rat model), limiting exposure of other tissues to TFV
CMX157 is rapidly and efficiently converted to the active antiviral, TFV diphosphate by liver cells, consistent with its improved antiviral activity and potential for dose reduction
CMX157 exhibits low potential for drug-drug interactions
About ContraVir Pharmaceuticals
ContraVir is a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies with two candidates in mid-to-late stage clinical development. ContraVir's lead clinical drug, FV-100, is an orally available nucleoside analogue prodrug that is being developed for the treatment of herpes zoster, or shingles, which is currently in Phase 3 clinical development. In addition to direct antiviral activity, FV-100 has demonstrated the potential to reduce the incidence of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN) in a Phase 2 clinical study. ContraVir is also developing CMX157, a highly potent analog of the successful antiviral drug tenofovir, for treatment of Hepatitis B. CMX157's novel structure results in decreased circulating levels of tenofovir, lowering systemic exposure and thereby reducing the potential for renal and bone side effects.
For further information, please contact:
Claire Sojda (media)
email@example.com; (212) 375-2686
SOURCE ContraVir Pharmaceuticals, Inc.